<DOC>
	<DOCNO>NCT00520676</DOCNO>
	<brief_summary>The purpose study compare combination pemetrexed carboplatin combination docetaxel carboplatin term survival without Grade 3 4 toxicity previously untreated patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patient locally advance metastatic ( Stage IIIB/IV ) NCSLC prior chemotherapy advance disease molecular target treatment Easter Cooperative Oncology Group ( ECOG ) performance status 0 2 Estimated life expectancy least 8 week Known suspected brain metastasis Concurrent administration tumor therapy Serious concomitant disorder Pregnancy breast feeding Inability unwillingness take folic acid vitamin B12 supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>